SEC Form 8-K Summary
Registrant: MedTech Acquisition Corporation, which intends to be renamed TriSalus Life Sciences, Inc. upon completion of its proposed business combination with TriSalus Life Sciences, Inc.
Reporting date: December 7, 2022. The filing reports under Item 5.07 the adjournment and voting results of a special stockholder meeting.
Business Context and Reporting Period
MedTech convened its special meeting of stockholders on December 7, 2022, but adjourned the meeting to 11:00 a.m. Eastern Time on December 12, 2022, without conducting other business. The adjournment was intended to provide additional time to solicit votes on extending MedTech’s business-combination deadline from December 22, 2022 to June 22, 2023, or an earlier date determined by the board.
On November 11, 2022, MedTech entered into a merger agreement with TriSalus Life Sciences, Inc. Under the agreement, a MedTech subsidiary would merge with TriSalus, with TriSalus surviving as a wholly owned subsidiary of MedTech.
Meeting and Voting Results
| Item | Result |
|---|---|
| Shares outstanding as of October 24, 2022 | 31,250,000, comprising 25,000,000 Class A shares and 6,250,000 Class B shares |
| Shares represented at the meeting | 23,253,915, or 74.41% of voting power |
| Adjournment proposal — For | 18,357,148 |
| Adjournment proposal — Against | 4,839,932 |
| Adjournment proposal — Abstain | 56,835 |
| Outcome | Approved; meeting adjourned to December 12, 2022 |
Financial Metrics and Liquidity
This filing does not provide current-period revenue, profit, cash flow, margins, debt, cash balances, liquidity measures, operating results, or other financial statement metrics. It does identify minimum cash following potential redemptions as a condition to completing the proposed business combination, but does not state the required amount.
Material Changes Versus the Prior Comparable Period
- The filing reports a procedural change rather than operating or financial performance: the special meeting was adjourned to seek additional votes.
- The proposed business-combination deadline is subject to an extension from December 22, 2022 to June 22, 2023, pending approval of the Extension Amendment.
- MedTech’s proposed merger with TriSalus, announced in November 2022, remains subject to specified conditions and approvals.
Outlook, Risks, and Contingencies
The filing contains no quantitative financial guidance. Completion of the business combination is subject to stockholder approval, satisfaction of the minimum cash condition after redemptions, governmental and regulatory approvals, including reimbursement approval, and other customary closing conditions.
- The transaction may not close on time or at all, including if the deadline is not extended.
- MedTech may fail to maintain its Nasdaq listing or obtain required financing.
- Redemptions could reduce available cash below the required minimum.
- The merger agreement could be terminated, or an alternative transaction could interfere with the proposed combination.
- TriSalus faces risks related to reimbursement, regulatory approval, clinical and preclinical development, commercialization, competition, market size, TriNav sales growth, funding, partnerships, and future growth.
- Legal proceedings, transaction costs, unfavorable market conditions, and failure to realize projected benefits or pro forma results could adversely affect investors.
Important Facts for Investors to Verify
- Whether the Extension Amendment was ultimately approved and the business-combination deadline extended.
- Whether the proposed MedTech–TriSalus merger received required stockholder, regulatory, reimbursement, and other approvals.
- The minimum cash condition, actual stockholder redemptions, and resulting transaction financing.
- The definitive merger terms, including ownership, valuation, dilution, financing, and any amendments or termination provisions.
- TriSalus’s current financial statements, cash runway, debt, revenue trends, TriNav sales, and clinical or regulatory status, which are not provided in this 8-K.